சீனா மருத்துவ அமைப்பு ஹோல்டிங்ஸ் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
China based CMS joins BaseLaunch as latest partner
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Starting its Industrial Investment in Biotech Companies, China Medical System (0867 HK) has Accelerated its Flywheel of Innovation
asahi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asahi.com Daily Mail and Mail on Sunday newspapers.
China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation
HONG KONG, Apr 05, 2021 - (ACN Newswire) - As the earnings season arrives, listed pharmaceutical companies are attracting much attention. China Medical System Holdings Limited (CMS, or Company) has released its annual results, with both revenue and profit higher than market expectations. According to its 2020 earnings results, turnover is up by 14.4% to RMB6.946 billion; net profit up by 30.7% to RMB2.556 billion; basic earnings per share up to RMB1.024, with a proposed final dividend of RMB0.20 per share.
In the past, influenced by expectations of the effects of China s centralized procurement policy and the Company s product transition, CMS s valuation in the capital market was once under pressure, but with the Company s strategic transformation from a CSO to an innovative pharmaceutical company, coupled with its own solid business growth, its share price has gained a signif
China Medical System: Accelerating Development and Stepping to a New Height Driven by Innovation
BriefingWire.com, 4/04/2021 - By Gelonghui
As the earnings season approaches, once again listed pharmaceutical companies are attracting the attention of the public. Recently, China Medical System Holdings Limited (CMS or the Company) has released its annual results, with both revenue and profit higher than market expectations. According to its 2020 annual results, turnover is up by 14.4% to RMB6.946 billion; net profit up by 30.7% to RMB2.556 billion; basic earnings per share up to RMB1.024, with a proposed final dividend of RMB0.20 per share.
In the past, influenced by expectations of the effects of Chinaâs centralized procurement policy and the Companyâs product transition, CMSâs valuation in the capital market was once under pressure, but with the Companyâs strategic transformation from a CSO to an innovative pharmaceutical comp
vimarsana © 2020. All Rights Reserved.